Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis

Clinical and Experimental Immunology

Volumn 152, Issue 2, 2008, Pages 280-284

  Sellner, J ^a,c   Greeve, I ^a   Findling, O ^a   Grandgirard, D ^b   Leib, S L ^b   Mattle, H P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atorvastatin; Immunomodulation; Interferon beta; Multiple sclerosis; Neuropharmacology

Indexed keywords

ATORVASTATIN; BETA INTERFERON; DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; INTERFERON BETA SERINE;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; IN VIVO STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANTIGENS, CD95; DRUG THERAPY, COMBINATION; FAS LIGAND PROTEIN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PYRROLES; SOLUBILITY; TREATMENT OUTCOME;

EID: 42049123689     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03630.x     Document Type: Article

References (24)

1. Fas SC, Fritzsching B, Suri-Payer E, Krammer PH. Death receptor signaling and its function in the immune system. Curr Dir Autoimmun 2006 9 : 1 17.
2. Aktas O, Prozorovski T, Zipp F. Death ligands and autoimmune demyelination. Neuroscientist 2006 12 : 305 16.
3. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003 15 : 185 93.
4. Zhu B, Luo L, Chen Y, Paty DW, Cynader MS. Intrathecal Fas ligand infusion strengthens immunoprivilege of central nervous system and suppresses experimental autoimmune encephalomyelitis. J Immunol 2002 169 : 1561 9.
5. Waldner H, Sobel RA, Howard E, Kuchroo VK. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J Immunol 1997 159 : 3100 3.
6. Bieganowska KD, Ausubel LJ, Modabber Y, Slovik E, Messersmith W, Hafler DA. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J Exp Med 1997 185 : 1585 94.
7. Pender MP. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 1998 351 : 978 81.
8. Hallal-Longo DE, Mirandola SR, Oliveira EC et al. Diminished myelin-specific T cell activation associated with increase in CTLA4 and fas molecules in multiple sclerosis patients treated with IFN-beta. J Interferon Cytokine Res 2007 27 : 865 74.
9. Rep MH, Schrijver HM, van Lopik T et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol 1999 96 : 92 100.
10. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006 6 : 358 70.
11. Blanco-Colio LM, Munoz-Garcia B, Martin-Ventura JL et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 2003 108 : 1506 13.
12. Blanco-Colio LM, Martin-Ventura JL, de Teresa E et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol 2007 27 : 168 74.
13. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005 58 : 840 6.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 : 1444 52.
15. Bilinska M, Frydecka I, Podemski R, Gruszka E. Fas expression on T cells and sFas in relapsing-remitting multiple sclerosis. Acta Neurol Scand 2003 107 : 387 93.
16. Sakai T, Inoue A, Koh CS, Osame M. Serum levels of apoptosis-related molecules in patients with multiple sclerosis and human T-lymphotropic virus Type I-associated myelopathy. J Interferon Cytokine Res 1999 19 : 999 1004.
17. Comi C, Leone M, Bonissoni S et al. Defective T cell fas function in patients with multiple sclerosis. Neurology 2000 55 : 921 7.
18. Macchi B, Matteucci C, Nocentini U et al. Defective Fas ligand production in lymphocytes from MS patients. Neuroreport 2001 12 : 4113 16.
19. Tanaka M, Suda T, Haze K et al. Fas ligand in human serum. Nat Med 1996 2 : 317 22.
20. Zang YC, Kozovska MM, Hong J et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol 1999 29 : 1692 700.
21. Neuhaus O, Hartung HP. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Rev Neurother 2007 7 : 547 56.
22. Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002 59 : 990 7.
23. Salama HH, Kolar OJ, Zang YC, Zhang J. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis. Mult Scler 2003 9 : 28 31.
24. Muldoon MF, Flory JD, Marsland A, Manuck SB, Whiteside TL, Rabin B. Effects of lovastatin on the immune system. Am J Cardiol 1997 80 : 1391 4.